This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bacheler, L. T.
Right arrow Articles by Abremski, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bacheler, L. T.
Right arrow Articles by Abremski, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2000, p. 2475-2484, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.

Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy

Lee T. Bacheler,* Elizabeth D. Anton, Phil Kudish, David Baker, Julie Bunville, Karen Krakowski, Laura Bolling, Monette Aujay, Xin Victoria Wang, Dawn Ellis, Mary F. Becker, Amy L. Lasut, Henry J. George, Daniel R. Spalding, Greg Hollis, and Kenneth Abremski

DuPont Pharmaceuticals Company, Experimental Station, Wilmington, Delaware 19880-0336

Received 11 February 2000/Returned for modification 13 April 2000/Accepted 22 June 2000

Efavirenz is a potent and selective nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT). Nucleotide sequence analyses of the protease and RT genes (coding region for amino acids 1 to 229) of multiple cloned HIV-1 genomes from virus found in the plasma of patients in phase II clinical studies of efavirenz combination therapy were undertaken in order to identify the spectrum of mutations in plasma-borne HIV-1 associated with virological treatment failure. A K103N substitution was the HIV-1 RT gene mutation most frequently observed among plasma samples from patients for whom combination therapy including efavirenz failed, occurring in at least 90% of cases of efavirenz-indinavir or efavirenz-zidovudine (ZDV)-lamivudine (3TC) treatment failure. V108I and P225H mutations were observed frequently, predominantly in viral genomes that also contained other nonnucleoside RT inhibitor (NNRTI) resistance mutations. L100I, K101E, K101Q, Y188H, Y188L, G190S, G190A, and G190E mutations were also observed. V106A, Y181C, and Y188C mutations, which have been associated with high levels of resistance to other NNRTIs, were rare in the patient samples in this study, both before and after exposure to efavirenz. The spectrum of mutations observed in cases of virological treatment failure was similar for patients initially dosed with efavirenz at 200, 400, or 600 mg once a day and for patients treated with efavirenz in combination with indinavir, stavudine, or ZDV-3TC. The proportion of patients carrying NNRTI resistance mutations, usually K103N, increased dramatically at the time of initial viral load rebound in cases of treatment failure after exposure to efavirenz. Viruses with multiple, linked NNRTI mutations, especially K103N-V108I and K103N-P225H double mutants, accumulated more slowly following the emergence of K103N mutant viruses.

* Corresponding author. Mailing address: DuPont Pharmaceuticals Company, E336/36B Experimental Station, Wilmington, DE 19880-0336. Phone: (302) 695-4278. Fax: (302) 695-9466. E-mail: lee.bacheler{at}dupontpharma.com.

Antimicrobial Agents and Chemotherapy, September 2000, p. 2475-2484, Vol. 44, No. 9
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Lai, M.-T., Munshi, V., Touch, S., Tynebor, R. M., Tucker, T. J., McKenna, P. M., Williams, T. M., DiStefano, D. J., Hazuda, D. J., Miller, M. D. (2009). Antiviral Activity of MK-4965, a Novel Nonnucleoside Reverse Transcriptase Inhibitor. Antimicrob. Agents Chemother. 53: 2424-2431 [Abstract] [Full Text]  
  • Herrera, C., Cranage, M., McGowan, I., Anton, P., Shattock, R. J. (2009). Reverse Transcriptase Inhibitors as Potential Colorectal Microbicides. Antimicrob. Agents Chemother. 53: 1797-1807 [Abstract] [Full Text]  
  • Garcia-Diaz, A., Blok, C., Madge, S., Booth, C., Tyrer, M., Bonora, S., Mahungu, T., Owen, A., Johnson, M., Geretti, A. M. (2008). Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. J Antimicrob Chemother 62: 1188-1190 [Abstract] [Full Text]  
  • Ceccherini-Silberstein, F., Svicher, V., Sing, T., Artese, A., Santoro, M. M., Forbici, F., Bertoli, A., Alcaro, S., Palamara, G., d'Arminio Monforte, A., Balzarini, J., Antinori, A., Lengauer, T., Perno, C. F. (2007). Characterization and Structural Analysis of Novel Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Involved in the Regulation of Resistance to Nonnucleoside Inhibitors. J. Virol. 81: 11507-11519 [Abstract] [Full Text]  
  • Dykes, C., Demeter, L. M. (2007). Clinical Significance of Human Immunodeficiency Virus Type 1 Replication Fitness. Clin. Microbiol. Rev. 20: 550-578 [Abstract] [Full Text]  
  • Nachega, J. B., Hislop, M., Dowdy, D. W., Chaisson, R. E., Regensberg, L., Maartens, G. (2007). Adherence to Nonnucleoside Reverse Transcriptase Inhibitor Based HIV Therapy and Virologic Outcomes. ANN INTERN MED 146: 564-573 [Abstract] [Full Text]  
  • Zhang, Z., Xu, W., Koh, Y.-H., Shim, J. H., Girardet, J.-L., Yeh, L.-T., Hamatake, R. K., Hong, Z. (2007). A Novel Nonnucleoside Analogue That Inhibits Human Immunodeficiency Virus Type 1 Isolates Resistant to Current Nonnucleoside Reverse Transcriptase Inhibitors. Antimicrob. Agents Chemother. 51: 429-437 [Abstract] [Full Text]  
  • Goffinet, C., Allespach, I., Keppler, O. T. (2007). HIV-susceptible transgenic rats allow rapid preclinical testing of antiviral compounds targeting virus entry or reverse transcription. Proc. Natl. Acad. Sci. USA 104: 1015-1020 [Abstract] [Full Text]  
  • Beerenwinkel, N., Drton, M. (2007). A mutagenetic tree hidden Markov model for longitudinal clonal HIV sequence data. Biostatistics 8: 53-71 [Abstract] [Full Text]  
  • Zhang, Z., Walker, M., Xu, W., Shim, J. H., Girardet, J.-L., Hamatake, R. K., Hong, Z. (2006). Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.. Antimicrob. Agents Chemother. 50: 2772-2781 [Abstract] [Full Text]  
  • Hossain, M. M., Parniak, M. A. (2006). In Vitro Microbicidal Activity of the Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) UC781 against NNRTI-Resistant Human Immunodeficiency Virus Type 1. J. Virol. 80: 4440-4446 [Abstract] [Full Text]  
  • Hazen, R. J., Harvey, R. J., St. Clair, M. H., Ferris, R. G., Freeman, G. A., Tidwell, J. H., Schaller, L. T., Cowan, J. R., Short, S. A., Romines, K. R., Chan, J. H., Boone, L. R. (2005). Anti-Human Immunodeficiency Virus Type 1 Activity of the Nonnucleoside Reverse Transcriptase Inhibitor GW678248 in Combination with Other Antiretrovirals against Clinical Isolate Viruses and In Vitro Selection for Resistance. Antimicrob. Agents Chemother. 49: 4465-4473 [Abstract] [Full Text]  
  • Vingerhoets, J., Azijn, H., Fransen, E., De Baere, I., Smeulders, L., Jochmans, D., Andries, K., Pauwels, R., de Bethune, M.-P. (2005). TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments. J. Virol. 79: 12773-12782 [Abstract] [Full Text]  
  • Ferris, R. G., Hazen, R. J., Roberts, G. B., St. Clair, M. H., Chan, J. H., Romines, K. R., Freeman, G. A., Tidwell, J. H., Schaller, L. T., Cowan, J. R., Short, S. A., Weaver, K. L., Selleseth, D. W., Moniri, K. R., Boone, L. R. (2005). Antiviral Activity of GW678248, a Novel Benzophenone Nonnucleoside Reverse Transcriptase Inhibitor. Antimicrob. Agents Chemother. 49: 4046-4051 [Abstract] [Full Text]  
  • Chen, R., Yokoyama, M., Sato, H., Reilly, C., Mansky, L. M. (2005). Human Immunodeficiency Virus Mutagenesis during Antiviral Therapy: Impact of Drug-Resistant Reverse Transcriptase and Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors on Human Immunodeficiency Virus Type 1 Mutation Frequencies. J. Virol. 79: 12045-12057 [Abstract] [Full Text]  
  • Palmer, S., Kearney, M., Maldarelli, F., Halvas, E. K., Bixby, C. J., Bazmi, H., Rock, D., Falloon, J., Davey, R. T. Jr., Dewar, R. L., Metcalf, J. A., Hammer, S., Mellors, J. W., Coffin, J. M. (2005). Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis. J. Clin. Microbiol. 43: 406-413 [Abstract] [Full Text]  
  • Hofman, M. J., Higgins, J., Matthews, T. B., Pedersen, N. C., Tan, C., Schinazi, R. F., North, T. W. (2004). Efavirenz Therapy in Rhesus Macaques Infected with a Chimera of Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1. Antimicrob. Agents Chemother. 48: 3483-3490 [Abstract] [Full Text]  
  • Kapoor, A., Jones, M., Shafer, R. W., Rhee, S.-Y., Kazanjian, P., Delwart, E. L. (2004). Sequencing-Based Detection of Low-Frequency Human Immunodeficiency Virus Type 1 Drug-Resistant Mutants by an RNA/DNA Heteroduplex Generator-Tracking Assay. J. Virol. 78: 7112-7123 [Abstract] [Full Text]  
  • Gao, Y., Paxinos, E., Galovich, J., Troyer, R., Baird, H., Abreha, M., Kityo, C., Mugyenyi, P., Petropoulos, C., Arts, E. J. (2004). Characterization of a Subtype D Human Immunodeficiency Virus Type 1 Isolate That Was Obtained from an Untreated Individual and That Is Highly Resistant to Nonnucleoside Reverse Transcriptase Inhibitors. J. Virol. 78: 5390-5401 [Abstract] [Full Text]  
  • Locatelli, G. A., Campiani, G., Cancio, R., Morelli, E., Ramunno, A., Gemma, S., Hubscher, U., Spadari, S., Maga, G. (2004). Effects of Drug Resistance Mutations L100I and V106A on the Binding of Pyrrolobenzoxazepinone Nonnucleoside Inhibitors to the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Catalytic Complex. Antimicrob. Agents Chemother. 48: 1570-1580 [Abstract] [Full Text]  
  • Gulick, R. M., Ribaudo, H. J., Shikuma, C. M., Lustgarten, S., Squires, K. E., Meyer, W. A. III, Acosta, E. P., Schackman, B. R., Pilcher, C. D., Murphy, R. L., Maher, W. E., Witt, M. D., Reichman, R. C., Snyder, S., Klingman, K. L., Kuritzkes, D. R., the AIDS Clinical Trials Group Study A5095 Team, (2004). Triple-Nucleoside Regimens versus Efavirenz-Containing Regimens for the Initial Treatment of HIV-1 Infection. NEJM 350: 1850-1861 [Abstract] [Full Text]  
  • Clavel, F., Hance, A. J. (2004). HIV Drug Resistance. NEJM 350: 1023-1035 [Full Text]  
  • Scott, P., Arnold, E., Evans, B., Pozniak, A., Moyle, G., Shahmenesh, M., White, D., Shirley, J., Cane, P., Pillay, D. (2004). Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother 53: 469-473 [Abstract] [Full Text]  
  • Collins, J. A., Thompson, M. G., Paintsil, E., Ricketts, M., Gedzior, J., Alexander, L. (2004). Competitive Fitness of Nevirapine-Resistant Human Immunodeficiency Virus Type 1 Mutants. J. Virol. 78: 603-611 [Abstract] [Full Text]  
  • Joly, V., Descamps, D., Peytavin, G., Touati, F., Mentre, F., Duval, X., Delarue, S., Yeni, P., Brun-Vezinet, F. (2004). Evolution of Human Immunodeficiency Virus Type 1 (HIV-1) Resistance Mutations in Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) in HIV-1-Infected Patients Switched to Antiretroviral Therapy without NNRTIs. Antimicrob. Agents Chemother. 48: 172-175 [Abstract] [Full Text]  
  • Wirden, M., Simon, A., Schneider, L., Tubiana, R., Paris, L., Marcelin, A. G., Delaugerre, C., Legrand, M., Herson, S., Peytavin, G., Katlama, C., Calvez, V. (2003). Interruption of Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Therapy for 2 Months Has No Effect on Levels of Human Immunodeficiency Virus Type 1 in Plasma of Patients Harboring Viruses with Mutations Associated with Resistance to NNRTIs. J. Clin. Microbiol. 41: 2713-2715 [Abstract] [Full Text]  
  • Huang, W., Gamarnik, A., Limoli, K., Petropoulos, C. J., Whitcomb, J. M. (2002). Amino Acid Substitutions at Position 190 of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Increase Susceptibility to Delavirdine and Impair Virus Replication. J. Virol. 77: 1512-1523 [Abstract] [Full Text]  
  • Trachtenberg, J. D., Sande, M. A. (2002). Emerging Resistance to Nonnucleoside Reverse Transcriptase Inhibitors: A Warning and a Challenge. JAMA 288: 239-241 [Full Text]  
  • Loemba, H., Brenner, B., Parniak, M. A., Ma'ayan, S., Spira, B., Moisi, D., Oliveira, M., Detorio, M., Wainberg, M. A. (2002). Genetic Divergence of Human Immunodeficiency Virus Type 1 Ethiopian Clade C Reverse Transcriptase (RT) and Rapid Development of Resistance against Nonnucleoside Inhibitors of RT. Antimicrob. Agents Chemother. 46: 2087-2094 [Abstract] [Full Text]  
  • Harrigan, P. R., Salim, M., Stammers, D. K., Wynhoven, B., Brumme, Z. L., McKenna, P., Larder, B., Kemp, S. D. (2002). A Mutation in the 3' Region of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase (Y318F) Associated with Nonnucleoside Reverse Transcriptase Inhibitor Resistance. J. Virol. 76: 6836-6840 [Abstract] [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»